PDA

View Full Version : NIH Guide Announcement



Daniel B. Sheffer
01-24-1992, 12:25 AM
The following message may be of interest to the readership of biomch-l:

NEUROLOGICAL MOTOR CONTROL AND MOTOR CONTROL DISORDERS: RESTITUTION
OF FUNCTION

NIH GUIDE, Volume 21, Number 3, Part II of II, January 24, 1992

PA: PA-92-36

P.T. 34; K.W. 0715140, 1002030, 0710085, 0705070, 0710050, 0715213

National Institute of Neurological Disorders and Stroke

PURPOSE

The National Institute of Neurological Disorders and Stroke (NINDS),
a component of the National Institutes of Health (NIH), invites
research grant applications through this Program Announcement (PA)
for support of research on neurological motor control, motor control
disorders, and the restitution of function. Applications covering a
broad range of activities in the neurological sciences from basic
research to clinical research are encouraged. It is expected that
regardless of approach, all studies will be focused on normal and
abnormal performance of the nervous system in regard to motor
control. This type of solicitation is issued to encourage
investigator-initiated research projects in areas of special
programmatic interest to the NINDS.

BACKGROUND

The NINDS is the principal NIH component for support of basic and
clinical research on the prevention, diagnosis, treatment, and
rehabilitation of neurological disorders. Disorders in motor control
occur as sequelae to many neurological and neuromuscular diseases and
disorders. Understanding these disorders and approaches to
restitution of function in patients with these disorders is difficult
because many elements of the nervous system interact to produce motor
control in healthy individuals. Motor control involves broad areas
of the central nervous system including the spinal cord, the
cerebellum, and motor areas of the cortex, basal ganglia, and
thalamus among others. Sensory input is also an important element in
motor control. In addition, it is being increasingly appreciated
that nerve-muscle interactions and the intrinsic properties of
muscles and tendons may play a significant role in motor control.
The understanding of motor control necessary for appropriate
treatment of its disorders requires a detailed understanding of the
individual elements of motor control systems and, equally, an
understanding of how the different components interact. This PA is
issued to encourage grant applications that cover a broad range of
motor disorders, areas of the nervous system, and levels of
integration but that share the common focus of motor control and its
disorders.

RESEARCH GOALS AND SCOPE

This announcement is issued to encourage and foster
investigator-initiated basic, clinical, and applied research on motor
control and its disorders. Examples of research objectives
appropriate for inclusion in applications responsive to this PA
include:

o Studies of the neurophysiological foundation of motor control;

o Studies of the biomechanics and neuromuscular physiology of motor
control including conscious and automatic control in humans or
animals;

o Studies of the role of sensory systems in motor control;

o Studies of the electrophysiological, neuroendocrine, and
biochemical foundation of motor control;

o Studies of the integration of motor, sensory, and central systems
in gait, postural control, and fine motor control such as hand
movements;

o Studies of the neurological dysfunctions in motor control
associated with cerebellar degeneration, hereditary ataxias,
demyelinating disorders, such as multiple sclerosis, and in
degenerative disorders such as Huntington's and Parkinson's disease;

o Studies of abnormal nervous system functioning after viral
infection, stroke, trauma, toxic insult, or in cerebral palsy and
post-poliomyelitis syndrome;

o Physiologic analysis of basic movement disorder mechanisms and
symptomatology, e.g., chorea, dystonia, rigidity, spasticity, and
tremor;

o Applied research directed at improving or restoring motor control
in neurologically impaired individuals;

o Studies of neurological locomotor abnormalities in AIDS,
neuropathies, atrophies, and other neurological diseases.

HEALTHY PEOPLE 2000

The Public Health Service (PHS) is committed to achieving the health
promotion and disease prevention objectives of "Healthy People 2000,"
a PHS-led national activity for setting priority areas. This PA,
Neurological Motor and Motor Control Disorders: Restitution of
Function, is related to the priority area of chronic disabling
conditions. Potential applicants may obtain a copy of "Healthy
People 2000" (Full Report: Stock No. 017-001-00474-0) or "Healthy
People 2000" (Summary Report: Stock No. 017-001-00473-1) through the
Superintendent of Documents, Government Printing Office, Washington,
DC 20402-9325 (telephone 202-783-3238).

MECHANISM OF SUPPORT

The support mechanisms for this research will be the individual
research grant (RO1), the First Independent Research Support and
Transition (FIRST) Award (R29), Research Career Development Award
(K04), Clinical Investigator Award (K08), and the program project
grant (P01). The number of awards to be made is dependent upon
receipt of a sufficient number of applications of high scientific
merit and upon availability of funds.

GENERAL REQUIREMENTS

SPECIAL INSTRUCTIONS TO APPLICANTS REGARDING IMPLEMENTATION OF NIH
POLICIES CONCERNING INCLUSION OF WOMEN AND MINORITIES IN CLINICAL
RESEARCH STUDY POPULATIONS

NIH and ADAMHA policy is that applicants for NIH/ADAMHA clinical
research grants and cooperative agreements will be required to
include minorities and women in study populations so that research
findings can be of benefit to all persons at risk of the disease,
disorder or condition under study; special emphasis should be placed
on the need for inclusion of minorities and women in studies of
diseases, disorders and conditions which disproportionately affect
them. This policy is intended to apply to males and females of all
ages. If women or minorities are excluded or inadequately
represented in clinical research, particularly in proposed
population-based studies, a clear compelling rationale should be
provided.

The composition of the proposed study population must be described in
terms of gender and racial/ethnic group. In addition, gender and
racial/ethnic issues should be addressed in developing a research
design and sample size appropriate for the scientific objectives of
the study. This information should be included in the form PHS 398
in Section 2, A-D of the Research Plan AND summarized in Section 2,
E, Human Subjects. Applicants/offerers are urged to assess carefully
the feasibility of including the broadest possible representation of
minority groups. However, NIH recognizes that it may not be feasible
or appropriate in all research projects to include representation of
the full array of United States racial/ethnic minority populations
(i.e., Native Americans (including American Indians or Alaska
Natives), Asian/Pacific Islanders, Blacks, Hispanics).

The rationale for studies on single minority population groups should
be provided.

For the purpose of this policy, clinical research includes human
biomedical and behavioral studies of etiology, epidemiology,
prevention (and preventive strategies), diagnosis, or treatment of
diseases, disorders or conditions, including but not limited to
clinical trials.

The usual NIH policies concerning research on human subjects also
apply. Basic research or clinical studies in which human tissues
cannot be identified or linked to individuals are excluded. However,
every effort should be made to include human tissues from women and
racial/ethnic minorities when it is important to apply the results of
the study broadly, and this should be addressed by applicants.

For foreign awards, the policy on inclusion of women applies fully;
since the definition of minority differs in other countries, the
applicant must discuss the relevance of research involving foreign
population groups to the United States' populations, including
minorities.

If the required information is not contained within the application,
the application will be returned.

Peer reviewers will address specifically whether the research plan in
the application conforms to these policies. If the representation of
women or minorities in a study design is inadequate to answer the
scientific question(s) addressed AND the justification for the
selected study population is inadequate, it will be considered a
scientific weakness or deficiency in the study design and will be
reflected in assigning the priority score to the application.

All applications for clinical research submitted to NIH are required
to address these policies. NIH funding components will not award
grants or cooperative agreements that do not comply with these
policies.

APPLICATION PROCEDURE

Applications must be submitted on the grant application form PHS 398
(Rev. 10/88, reprinted 9/89) and will be accepted on any of the three
receipt dates for research grant applications, February 1, June 1,
and October 1.

Application kits are available at most business and grants/contracts
offices and may be obtained from the Office of Grants Inquiries,
Division of Research Grants, National Institutes of Health, Westwood
Building, Room 449, Bethesda, MD 20892, telephone (301) 496-7441.

On the first (face) page, item 2, of the application, the word "yes"
must be checked and the title and number of the announcement typed in
the space provided: NEUROLOGICAL MOTOR CONTROL AND MOTOR CONTROL
DISORDERS: RESTITUTION OF FUNCTION, PA-92-36.

Applicants from institutions that have a General Clinical Research
Center (GCRC) funded by the NIH National Center for Research
Resources may wish to identify the GCRC as a resource for conducting
the proposed research. In such a case, a letter of agreement from
either the GCRC program director or Principal Investigator must be
included with the application.

The original and six copies of the application must be sent or
delivered to:

Application Receipt Office
Division of Research Grants
National Institutes of Health
Westwood Building, Room 240
Bethesda, MD 20892**

REVIEW PROCEDURES

Applications will receive institute and initial review group (IRG)
assignment on the basis of established Public Health Service referral
guidelines. Applications will be reviewed for scientific and
technical merit by an IRG. Following IRG review, the applications
will receive a second-level review by an appropriate Council/Board.
Applications will compete for available funds with all other approved
applications assigned to the institute.

REVIEW CRITERIA

The standard review criteria will be used to assess the scientific
merit of applications. The IRG will be reviewing the adequacy of
protection of human subjects, the humane care of animals, and
biosafety conditions. In clinical research studies, reviewers also
will be evaluating the adequacy of the inclusion of women and
minorities in the study populations.

STAFF CONTACT

Investigators are encouraged to contact:

Dr. William Heetderks
Division of Fundamental Neuroscience
National Institute of Neurological Disorders and Stroke
Federal Building, Room 9l6
Bethesda, MD 20892
Telephone: (301) 496-5745

Dr. A. P. Kerza-Kwiatecki
Division of Demyelinating, Atrophic, and Dementing Disorders
National Institute of Neurological Disorders and Stroke
Federal Building, Room 804
Bethesda, MD 20892
Telephone: (301) 496-1431

Dr. Floyd J. Brinley, Jr.
Division of Convulsive, Developmental, and Neuromuscular Disorders
National Institute of Neurological Disorders and Stroke
Federal Building, Room 816
Bethesda, MD 20892
Telephone: (301) 496-6541

Dr. Patricia A. Grady
Division of Stroke and Trauma
National Institute of Neurological Disorders and Stroke
Federal Building, Room 8A10
Bethesda, MD 20892
Telephone: (301) 496-4226

For fiscal and administrative matters contact:

Kathleen Howe
Grants Management Specialist
National Institute of Neurological Disorders and Stroke
Federal Building, Room 1004
7550 Wisconsin Ave.
Bethesda, MD 20892
Telephone: (301) 496-9231

AUTHORITY AND REGULATIONS

This program is described in the Catalog of Federal Domestic
Assistance No. 93.854 - Biological Basis Research in Neurosciences,
and 93.853 - Clinical Research related to Neurological Disorders.
Grants will be awarded under the authority of the Public Health
Service Act, Title III, Section 301 (Public Law 78-410, as amended;
42 USC 241) and administered under PHS grants policies and Federal
Regulations at 42 CFR Part 52 and 45 CFR Part 74. This program is
not subject to the intergovernmental review requirements of Executive
Order 12372 or a Health Systems Agency review.

- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
Daniel B. Sheffer, Ph.D., Head BITNET R1DBS@AKRONVM
Department of Biomedical Eng. INTERNET R1DBS@VM1.CC.UAKRON.EDU
University of Akron Telephone 216 972 6650
AKRON, OHIO 44325-0302 Telefax 216 374 8834